Summary Decay-accelerating-factor (DAF, CD55), a phosphatidyl-inositol anchored glycoprotein, is a member of the cell membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. DAF was found expressed on cells that are in close contact with serum complement proteins, but also on cells outside the vascular space and on tumour cells. Using CD55(BRIC110) and CD55(143-30) we show here that DAF(CD55) is only sporadically expressed on the luminal surface of normal colonic epithelium. However, 5/20 adenomas expressed DAF(CD55) on the cell surface of all tumour cells, 5/20 adenomas were completely negative, 10/20 adenomas expressed DAF(CD55) in various amounts. DAF(CD55) was expressed in various intensities on almost all tumour cells of the colon carcinoma cell line HT29. In 5/88 colorectal carcinomas DAF(CD55) was localised on the apical cell surface of all tumour cells, 31/88 were completely negative, 52/88 expressed DAF(CD55) in parts of their neoplastic populations. There was no correlation between the tumour grading, staging and location and the mode of DAF(CD55) expression, but DAF(CD55) was found more often in mucinous carcinomas (P= 0.007).
During the complement cascade activation complement fragments can be deposited on autologous cells that are not the desired target (Davitz et al., 1986) . In order to avoid the destruction of cells by complement, there are several membrane bound regulatory proteins that inhibit the complement cascade activation (Kinoshita, 1991) . One regulatory protein of the C3/C5 convertase is the 'decay accelerating factor' (DAF) (Lublin & Atkinson, 1989) . DAF is a phosphatidylinositol anchored cell membrane protein (Low, 1987 ) with a Mr of 70 kDa on erythrocyte membranes (Nicholson-Weller et al., 1982) . The DAF gene is located in the complementregulatory locus on the long arm of chromosome 1 (Lublin et al., 1987) . DAF blocks the C3 and C5 convertases of the classical and alternative complement pathway inhibiting the formation and promoting the catabolism of the C3 (C4b2a, C3bBb) and C5 complex (C4b2a3b, C3bBb3b) on autologous cells (Medof et al., 1984; Kinoshita et al., 1985; 1986; Fujita et al., 1987; Mold et al., 1990) . DAF was first isolated from erythrocyte membranes (Nicholson-Weller et al., 1982) and was also found on cells with close contact to serum complement proteins, on leucocytes, monocytes, platelets (Nicholson-Weller et al., 1985; Berger & Medof, 1987; Davis et al., 1988) and endothelial cells (Asch et al., 1986) . Recently DAF was also found in extravascular cells and tissues , in the myocard (ZimInermann et al., 1990) , in mesothelial cells, in the epithelium of the urogenital tract (Quigg et al., 1989) and gastrointestinal tract and fibrillar structures of the extracellular matrix (Werth et al., 1988; Sayama et al., 1991) . DAF is also expressed on the cell surface of malignant tumours, in various transformed cell lines of the myeloid, T and B cell origin (Hadam, 1989) and in some solid tumour cell lines, in melanomas, breast carcinomas (Cheung et al., 1988) , renal cell carcinomas (Terachi et al., 1991) and in HeLa tumour cells . DAF-positive tumour cells were found to be more resistant against complement cytotoxicity in the presence of autologous antibodies on their surfaces than were DAF-negative tumour cells (Cheung et al., 1988; Terachi et al., 1991) . DAF was therefore suggested as a protecting protein for tumour cells against complement-mediated cytotoxicity in vivo. Although the epithelium of the lower gastrointestinal tract was reported to express DAF , studies focussing on the expression of DAF in colorectal carcinomas are still missing. The present study therefore aims at investigating the expression of DAF in adenomas and colorectal carcinomas in situ and in the colon carcinoma cell line HT29 in vitro. (Dukes & Bussey, 1958; Hermanek & Sobin, 1987; Jass & Sobin, 1987 and a streptavidin-biotinylated peroxidase complex (Amersham). 3-Amino-9-ethylcarbazole (AEC) and N'N'-dimethylformamid (DMF) were obtained from Sigma Chemical Co. (St Louis, MO). The mAbs were diluted I:1000 in phosphate-buffered saline (PBS), biotinylated sheep antibody to mouse immunoglobulin was diluted 1:50 in PBS, and the streptavidin peroxidase complex was diluted 1:100. Incubation times were 1 h at room temperature for the primary antibody and 30 min for the second and third step reagents. Using AEC as the chromogen (0.4 mg ml-' in 0.01% H202 for 30min), the peroxidase reaction caused an intense red precipitate. The sections were rinsed in tap water, counterstained in Harris' hematoxylin and mounted with glycerol gelatin. Isotype-matched controls with irrelevant mAb were carried out on a limited number of normal mucosae and colon carcinomas and revealed no isotypeassociated side reaction in or on epithelial cells. Each frozensection series contained a negative control without the primary reagent; staining was observed solely in granulocytes whose endogenous peroxidase was not blocked for the benefit of optimal antigenicity, and to a much lesser extent in some epithelial areas due to endogeneous biotin.
Material and methods

Immunohistochemistry
Evaluation A semiquantitative evaluation system was used to determine the antigen expression in normal, adenoma, and carcinoma tissue and cells. Antigen expression was scored ' + ' whenever specific staining was detectable, and '-' when no antigen was detectable. To evaluate the amount of stained cells, a semiquantitive scoring system was established: ' + > -' indicates that stained cells clearly outnumbered the unstained cells; ' + / -' indicates that positive and negative cells were found in equal proportions; '-> +' means that unstained cells outnumbered the stained cells. According to this system, the antigen expression was correlated with tumour grade, type, stage and location of the tumour along the large bowel. The Fisher's exact test was applied for statistical analysis.
Flow cytometry For flow cytometry 1 x 106 cells of HT29 were used per probe. Cells were suspended in FACS-medium containing RPMI, FCS, NaH3 and HEPES buffer. HEA 125, a monoclonal antibody which detects an epithelium-specific glycoprotein, Egp34, in normal and neoplastic transformed epithelial cells (Momburg et al., 1987) was used as positive control. CD53 (HD77), a monoclonal antibody which detects the leucohistiocytic population and a probe without the primary antibody were used as negative controls. Cells were incubated with the CD55 antibody BRIC 110 diluted 1:200, and after three washing steps with the polyclonal FITCcoupled goat-anti-mouse antibody (Dianova Hamburg, Germany) diluted 1:50. The incubation time for each antibody was 1 h. After three washing steps propidium jodide (1 ;tg ml-' diluted in FACS-medium) was used for gating out the living cells. Flow cytometry was performed on a FACScang (Becton Dickinson) with the LYSYS II software programme.
Results
The expression of DAF(CD55) in normal colonic mucosa, in adenomas and carcinomas was immunohistochemically studied with mAb BRIC1 10. Previous studies found DAF expressed in the epithelium of the lower gastrointestinal tract , we found DAF(CD55) only sporadically localised in the epithelium of 3/20 normal colonic mucosae with CD55 BRIC110. In these three cases DAF(CD55) was expressed in small foci on the luminal surface of the epithelium in the upper parts of the crypts. A control study was performed with the mAb 143-30, another CD55 antibody which was also characterised on the IVth Workshop on Leucocyte Typing (Hadam, 1989) . MAb 143-30 like BRIC110, revealed that DAF(CD55) was only sporadically expressed in the normal colonic epithelium (Figure la,b) . In the normal gut wall mAb BRICI 10 detected DAF(CD55) in fibrillar structures and fibroblasts, particularly in the submucosa, in nerve fibres, in reticular cells of lymph follicles and weakly in some endothelial cells; smooth muscle cells of the gutwall and vessel wall, ganglion cells, B cells of lymph follicles, T cells and plasma cells were negative. MAb 143-30 showed similar results; in addition, endothelial cells were somewhat stronger positive and B cells of lymph follicles were strongly positive. It is not excluded that, in analogy to other DAF mAbs (Kinoshita et al., 1985) , BRICl10 and 143-30 although both reacting with the DAF molecule (Hadam, 1989) DAF(CD55) expression, three of which had more positive cells than negative ones. Two further cases contained positive and negative tumour cells in about equal proportions and five others had more negative tumour cells than positive ones (Table I) . DAF(CD55) was essentially localised on the luminal cell surface ( Figure 2a) ; occasionally, apico-lateral and baso-lateral cell surfaces were positive, too (Figure 2b,c (Figure 3c ). In the stroma there was strong expression of DAF(CD55) in peritumorous fibrillar structures and fibroblasts (Figure 3b ). There was no statistical correlation between presence vs absence of DAF(CD55) and the tumour grading or staging. However, DAF(CD55) was more frequently expressed in mucinous carcinomas (P = 0.007, Fisher's exact test). Finally, there was no statistical correlation between the mode of DAF (CD55) (CD55) was broader than that of the positive control Egp34 (HEA125), a broadly expressed but epithelium specific glycoprotein (Momburg et al., 1987) , because of the heterogeneous antigen density of DAF(CD55) on the tumour cell population (Figure 4b ). fibrillar structures, especially in the submucosa, while DAF(CD55) was only sporadically detected in the epithelium of 3/20 colon specimens. In these three cases DAF(CD55) was expressed in small foci of epithelial cells carrying the molecule on the luminal cell surface. In a recent study reporting on DAF expression in the a b Discussion C Although DAF was formerly found only on cells with close contact to serum proteins, the extensive study showed that DAF is broadly expressed in cells, tissues and fluids outside the vascular space. We investigated the expression of DAF(CD55) in 20 normal colonic tissues by an immunohistochemical technique using the murine mAb BRIC110 (Spring et al., 1987; Hadam, 1989 ). BRIC110 recognises a glycoprotein which was formally found on erythrocytes, leucocytes, platelets and several haematopoietic cell lines. This glycoprotein carries Cromer-related blood group antigens on normal erythrocytes and is absent or altered on erythrocytes of patients with the Inab phenotype (Spring et al., 1987) . We observed strong DAF(CD55) reactivity in (Lisanti et al., 1989) . DAF was also found expressed in several other carcinomas, HeLa cells and breast carcinomas (Cheung et al., 1988 (Cheung et al., 1988 
